Patents by Inventor Jules Jacob

Jules Jacob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220211668
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
  • Patent number: 11160786
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: November 2, 2021
    Assignee: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Publication number: 20200030242
    Abstract: A pharmaceutically acceptable oral dosage form for delivery of an agent to an intestinal site has one or more active agent regions having an active agent to be delivered to the intestinal site, one or more drying agent regions having at least one drying agent therein capable of drying an area about the intestinal site, the one or more drying agent regions being separate from the one or more active agent regions, and a protective coating at least partially covering a surface of the form. The dosage form has a fluid uptake capacity as measured for the entire dosage form when immersed in a fluid media according to a Dosage Form Fluid Uptake Assay of at least about 20 g fluid per dosage form.
    Type: Application
    Filed: February 3, 2017
    Publication date: January 30, 2020
    Inventors: Daniel BONNER, John JANTZ, Peter TRAN, Rachel SHAPIRO, Nicholas PILLA, Jules JACOB, Braden KUO, Colin Rober GARDNER, Padmaja SHIVANAND, Jacob BARLOW, Lisa Viana FERREIRA
  • Patent number: 10420785
    Abstract: A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: September 24, 2019
    Assignee: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules Jacob, Lauren Beach, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant
  • Publication number: 20180296479
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 18, 2018
    Applicant: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Patent number: 10028909
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: July 24, 2018
    Assignee: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
  • Publication number: 20170258763
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 14, 2017
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
  • Patent number: 9744137
    Abstract: The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and improved pharmacokinetics are disclosed. A once-a-day administration of topiramate is advantageous over the multiple dose regimen both in terms of patient compliance and reduced adverse events, thus providing better treatment of the conditions for which the topiramate is indicated.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: August 29, 2017
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Avinash Nangia, Daya D. Verma, Jules Jacob
  • Publication number: 20170202807
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 20, 2017
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
  • Publication number: 20170172919
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 22, 2017
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Patent number: 9669009
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: June 6, 2017
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Patent number: 9616018
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: April 11, 2017
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
  • Publication number: 20160361335
    Abstract: A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
    Type: Application
    Filed: August 23, 2016
    Publication date: December 15, 2016
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Lauren BEACH, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT
  • Patent number: 9492380
    Abstract: A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: November 15, 2016
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Lauren Beach, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant
  • Publication number: 20160250145
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: February 17, 2016
    Publication date: September 1, 2016
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Publication number: 20160220534
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Norman COYLE, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT, Nemichand B. JAIN
  • Patent number: 9339489
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: May 17, 2016
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Norman Coyle, Thomas G West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Patent number: 9314429
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: April 19, 2016
    Assignee: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
  • Publication number: 20150366802
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: August 27, 2015
    Publication date: December 24, 2015
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Publication number: 20150366801
    Abstract: A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
    Type: Application
    Filed: August 27, 2015
    Publication date: December 24, 2015
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Lauren BEACH, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT